Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24171103 | 1.00 | HDAC1 (0.39) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171110 | 1.00 | HDAC1 (0.39) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171001 | 0.83 | HRH3 (0.34) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171113 | 0.83 | HRH3 (0.34) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL23710203 | 0.83 | HRH3 (0.34) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171012 | 0.80 | HRH3 (0.33) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171579 | 0.80 | HRH3 (0.33) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL24171580 | 0.80 | HRH3 (0.33) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL23710151 | 0.79 | ACKR3 (0.40) | HDAC1HDAC8HDAC6ACKR3HRH3 | |
| SCHEMBL22236810 | 0.79 | ACKR3 (0.40) | HDAC1HDAC8HDAC6ACKR3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HDAC1 265/4885HDAC8 818/4885HDAC6 161/4885 |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | HDAC1 468/4885HDAC8 501/4885HDAC6 310/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | HDAC1 1272/4885HDAC8 3012/4885HDAC6 1154/4885 |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | HDAC1 3153/4885HDAC8 2822/4885HDAC6 1945/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HDAC1 265/4885HDAC8 818/4885HDAC6 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.